MedTech Innovator Asia Pacific LIVE

Sarah currently oversees the organization and operations of Opharmic Technology, a young medtech company specialised in the development of non-invasive ultrasonic medical platform technology. Skilled in pharmaceutical research and engineering, she was a researcher on drug delivery and formulation at the Chinese University of Hong Kong School of Medicine, and Jacobson’s Pharma Group prior to joining Opharmic. With strong interest in biotechnology and computational science and Sarah has previously founded a UX design and digital marketing firm during her university studies with a holistic clientele ranging from local biotech startups to international hardware companies. Opharmic Technology was the Grand Prize Winner for MedTech Innovator Asia Pacific program in 2021.

Rohan Dixit is founder and CEO of Lief (getlief.com) a discreet sensor patch that gives you control over your natural stress response. Formerly a Harvard and Stanford neuroscientist, Rohan studied the effect of meditation on the structural and functional properties of the human brain. His companies have helped thousands of American patients decrease stress, anxiety and chronic pain safely and without drugs.

Wei is a Principal of Johnson&Johnson Innovation- JJDC, the corporate venture group of J&J. She initiates and manages equity investments in biopharma, medical device, and consumer health, to drive innovation and fuel new and sustainable businesses. Prior to joining JJDC, Wei was a Senior Associate at Illumina Ventures with a focus on genomics-enabled precision medicine including therapeutics, diagnostics, and life science tools. Prior to that, she was the Director of Healthcare Investment and Business Development of BOE Ventures where she focused on VC fund investment, direct investment, and business development opportunities at the intersection of technology and life sciences. Before becoming an investor, Wei was a R&D project lead at NuGEN Technologies (later acquired to become TECAN Genomics). Wei received her Ph.D. from UCLA in Biological Chemistry and completed her postdoctoral research in the Department of Pathology at Stanford University. She received a Bachelor of Science in Biological Sciences from Peking University, China.

Joseph is the Managing Partner of Verge HealthTech Fund focusing on early stage healthcare technology companies relevant to emerging markets. Prior to this, Joseph was a scientist researching new cancer therapies, a medical device entrepreneur, and a management consultant for Oliver Wyman where he led life sciences and digital health across Asia. He has 19 scientific publications, 3 patents, and has made investments in 20 healthcare technology companies to date.

Joseph has a PhD from the University of Toronto, and an MBA from the Richard Ivey School of Business.

Alan Goh is the CEO of NDR Medical Technology, a medtech start-up that develops surgical robotics to assist surgeons during minimally invasive surgery. Driven by Artificial Intelligence and Medical Image Analysis to automate the needle targeting procedure, improves the clinical outcome, reduces radiation exposure and overall operation time. Medical Robotics will ensure surgeons of all experiences to be able to perform complex and high-risk surgery with ease. NDR is conducting clinical trials with various hospitals in Asia.

Graduated from Nanyang Technological University (NTU) with Bachelor of Engineering specializing in Mechatronics; together with a professional Graduate Diploma in medical technology manufacturing and completed courses in Charter Financial Analyst. He started his career in A*Star as a research engineer working on advance test equipment with the industry and was awarded the Outstanding Team Award in 2007 for his outstanding performance. He further advanced his career in the industry on product application, gained in-depth manufacturing experience and received Six-Sigma Green belt. Before starting NDR, he was a commercialization manager responsible for incubating and seeding medtech/biotech startups, developing business plan as well as supporting in medtech product development.

Joe Muldoon is the Chief Executive Officer for FAST BioMedical, a privately held, clinical stage medical company currently developing technology for quantifying plasma volume and kidney function. He leverages 27 years of experience, from technology start-ups to publicly traded multi-national companies. He has worked with many high-growth entrepreneurial companies as a Board advisor, investor, and CEO. He previously served as an Entrepreneur in Residence of the Indiana Venture Center and President of Brightpoint North America (NASDAQ:CELL) Mr. Muldoon has a Bachelor of Science in Business from Indiana University’s Kelley School of Business, where he is a frequent panelist and speaker for MBA programs. He serves on the Boards of Confluence Pharmaceuticals, Heart Reach Carmel and FAST BioMedical. He has previously served on the Boards of TGX Medical, Jameson, Inc., Venture Club of Indiana, and InfoDynamics.

Alex is a business leader, aerospace engineer and company director with experience in technical and management roles. He spent the first decade of his career working on projects for Lockheed Martin, Boeing and Airbus in the United States and Australia, before undertaking an MBA at the Melbourne Business School in 2014 to broaden his management skills and experience.

Along with five co-founders (Brad, Christiane, Mubin, Shing & Wei), Alex created Navi Medical Technologies in 2017 to commercialise technology that helps doctors and nurses care for critically ill newborns. Over the last two years Alex has led the company to raise over $2 million of early stage Angel, VC and grant funding to support research and development activities within Navi.

In his spare time Alex is committed to a number of volunteer roles, holding board positions in NFPs Pangea Global Health Education and the Melbourne Space Program, and is an innovation coach for the Melbourne Business School’s Executive Education program.

Yan Lin is a global citizen with experience building medtech businesses and technologies across Europe, APAC, and North America. An independent thinker and highly self-motivated, Yan Lin is often deployed into opaque and/or dynamic situations to bring clarity and an independent assessment. Using a mixture of analysis techniques, data, and her networks across the industry, Yan Lin defines strategic directions and a tactical responses for her employers and clients. Besides her commercial acumen, Yan Lin has practical experience developing new medical technologies for both developed and developing market applications. She enjoys enabling and accelerating the commercialization process by contributing her experience, knowledge, and network to product teams with the ultimate goal of bringing life saving technologies to patients as quickly as possible.

Rahul leads Cambridge Consultants global medical device business. Our teams help clients transform the future of surgery by developing smart implants, robotics & navigation systems, advanced critical care equipment, and digital surgery platforms.

Rahul’s passion is leading teams to combine business strategy, clinical science, and advanced technology to address unmet needs of patients, surgical teams, and hospitals in global markets. He has led over 30 complex programs across strategy, M&A, R&D, and manufacturing for multiple Class II and III medical devices. He has deep domain expertise in laparoscopy, endoscopy, surgical robotics, neurostimulation, cardiac rhythm management, surgical oncology, colorectal, bariatric, orthopedics, and cardiovascular products.

Dr. Langston Suen is the CEO and founder of Opharmic Technology. Founded in 2016, Opharmic is striving towards an ambitious goal: to replace horrifying eye injections around the world with our patented non-invasive ultrasound system. Based on over a decade of research and development, the team has successfully developed extensive drug delivery applications in the ophthalmology space. From technology and product customisation, to clinical development and regulatory strategies, Opharmic offers turnkey solution to pharma partners around the world to adopt cutting-edge technology in their new or existing pipelines.

Langston holds a Masters Degree in Chemical Engineering and a Ph.D in Chemical Engineering and Nanotechnology, both from the Hong Kong University of Science and Technology.

Jim Warren joined Jabil in 1998 after graduating from the University of Florida with a Finance and Economics degree and continues his education with ASQ as a Black Belt. Jim started as a Manager in Training, as part of the Jabil Emerging Leaders (JEL) Development program.
During his time in the JEL program Jim was rotated through cross-functional positions in Operations, Inventory Control, Supply Chain, Planning, Workcell Management, Design, Quality and Business Development in our St. Petersburg, FL Manufacturing site. The JEL program provided Jim experiential learning of our core competencies that serve as the foundation for his ability to create differentiated solutions for his customers.
After completing the JEL program Jim transitioned into a Supply Chain Development role in 2005. During that time Jim lived in Malaysia as well as China as he supported Jabil EMS and Jabil Green Point as a Director of Supply Chain. In each of his customer engagements Jim was able to create significant relationships and opportunities in de-risking our customer’s supply chains.
In 2015 Jim joined the Jabil Healthcare division as a Business Unit Director and now leads business teams in the US, Mexico, Ireland, Singapore and China.
Over the past year Jim’s scope has increased to add additional customers and a larger footprint in Asia. With view to extend his experience in other divisions, Jim is a contributor to Jabil’s website with insightful commentary on how medical and consumer behavior guide our development and design efforts at Jabil.

Based in Shanghai, China, a proven sales leader with over 15 years of experience in medical device, diagnostic market. With engineering background, coupled with strong industry and regulatory knowledge, providing winning solutions to global and asia-leading healthcare companies in product design/development to commercial supply.

As a signal processing engineer, I am passionate by the power of algorithm and belive that IoT and mobile phones will democratize medicine globally.

I was a researcher and postgrad student at NTU under the supervision of Prof Pina. We worked on biomedical signal processing and partnered with Tan Tock Seng Hospital (TTSH) for data collection and medical validation. Today I am e full-time co-founder running Biorithm, founded with and Dr. Foo and Prof. Pina.
at Biorithm, We enable mobile monitoring and detection of cardiac abnormalities via the use of monitoring devices, by providing software that incorporates diagnostic expertise for monitoring and detection of an acute event in cardiology and obstetrics field.

Chris Rao is the Senior Vice President of Research and Clinical Development of Alira Health. He has over 15 years of experience in clinical research, including roles in project management, monitoring, and data management, and has held leadership positions managing both domestic and international teams. He is responsible for new business and project activities for Alira Health’s internal CRO, regulatory, and CMC practices, and works with new and current clients to define corporate and scientific strategy, blending a commercial and clinical approach. Prior to Alira Health, Chris previously served as an Associate Director at the boutique oncology CRO, Clinical Assistance Programs (CAP) with a focus on clinical trial design and management and worked previously as a consultant analyst at Stone-Crowne Associates, performing pharmaceutical marketing data analysis for large pharma clients such as Johnson & Johnson as well as corporate financial analysis for MIT and Harvard University. He is a certified Clinical Project Manager and Clinical Research Associate.

Alex Budiman is the VP of Regulatory Affairs, Greater Asia for Becton Dickinson (BD). He had previous leadership roles in Quality, Business Unit, R&D and Operations. He worked for J&J, Medtronic and Bristol Myers Squib in the US and Biosensors International in Singapore before joining BD in 2017. Alex has served as a vice chair of APACMed RA committee since 2020.

Nada joined Experien Group (now Veranex) in 2017 after working 12 years at the FDA’s Center for Devices and Radiological Health (CDRH). Since 2010 she had been a CDRH senior science health advisor in the Center Director’s office. Nada combines her deep institutional knowledge with innovative approaches to help companies successfully communicate product information to the FDA throughout the total product life cycle. Leveraging her years of reviewer experience and broad FDA exposure, she develops actionable premarket strategies to guide programs through successful submission. She also orchestrates compliance activity. While at the FDA, Nada led postmarket investigations for OB-GYN devices, wrinkle fillers, tanning devices, breast implants, negative pressure wound therapy (NPWT) devices, and metal-on-metal hip implants, and she applies this knowledge to help companies effectively manage postmarket requirements.

At Veranex, Nada helps medical device and combination product manufacturers generate regulatory/clinical road maps for success. Building upon her strong engineering background, she helps companies devise and position product performance testing and/or clinical studies to achieve major milestones.

Nada initiated her career at Biomat Sciences as an R&D engineer supporting dental products. She joined CDRH’s Office of Device Evaluation (ODE) in 2004 and led FDA review teams for first-of-kind (and sometimes controversial) devices, including a silicone gel-filled breast implant PMA, a drug-eluting neurovascular stent IDE, and two novel neurological stent HDEs for the treatment of atherosclerotic disease. As a Senior Science Health Advisor at CDRH, Nada led cross-Center and agency programs for the advancement of the FDA’s mission, including the Health of Women (HoW) program, the Network of Experts program, and the Patient Preference Initiative. She collaborated with the Center for Tobacco and the National Institutes of Health (NIH) to improve regulatory efficiency and to strengthen data collection, and she was the CDRH liaison and subject matter expert to the FDA’s Office of Women’s Health (OWH) and the Office of Minority Health (OMH).

Nada holds a B.E. and an M.S. in biomedical materials science and engineering from Queen Mary College, University of London. She earned her MPH from Johns Hopkins Bloomberg School of Public Health. Nada is a Certified Quality Improvement Associate (CQIA) and a Certified Quality Auditor (CQA) from the American Society for Quality (ASQ).

Anand is a healthcare industry veteran with more than 22 years of multidisciplinary experience in pharmaceuticals and medical devices. His experience ranges from sales, marketing, strategic planning, pricing and market access, and general management at global, regional and local levels in Singapore, Switzerland, Russia & India. Prior to founding ANSEA, he was the Regional Head of Market Access / Government Affairs Asia for Novartis Oncology & then for Alcon Asia/Russia, including Country GM for Alcon Singapore. He has conceptualized several patient access programs, public-private partnerships and stakeholder engagement initiatives to help bring innovative therapies to patients in Asian countries. He is an engineer with MIB from IIFT, Delhi and MBA from IMD, Lausanne, Switzerland.

Yvonne Lee is the Regional Director of Health Economics and Market Access in Asia Pacific for Cardiovascular and Specialty Solutions at Johnson & Johnson. She holds a PhD in Medicine from University of New South Wales, Australia and Master of Public Health from Mount Sinai School of Medicine, New York. Her core competencies are development and application of health economic models, generate local real- world clinical evidence, quantify burden of disease, drive value-based reimbursement and patient access to innovative medical technologies across Asia Pacific. Yvonne has more than 16 years of working experience across different type of organization including academia, government, pharmaceutical and medtech industry around the globe. She has established track record publications and worked in the following therapeutic areas; oncology, infectious disease, diabetes, neuroimmunology disorders, cardiovascular and stroke. She received further training in cancer epidemiology at International Agency for Research on Cancer (IARC), World Health Organization (WHO), patient centered care at US Patient-Centered Outcome Research Institute (PCORI) and she is an alumni of Eureka 3rd International Certificate Program in Translational Medicine (2010). Yvonne believes in multi-stakeholder collaborations to deliver quality care and putting patient first in the treatment paradigm.

Hin Au is an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. Hin provides IP strategy and counseling services to clients in a wide range of technical fields, including MedTech, digital health, biotech, medical/diagnostic devices, software, robotics, autonomous vehicle technologies, and clean energy. He has assisted many clients with building their patent portfolios and securing key strategic patents. Hin has hands-on engineering industry experience, having previously worked as an R&D engineer for six years at large U.S. semiconductor corporations. A native of Singapore, Hin is also fluent in Mandarin and Cantonese.

Mr. Sheppard has been a leader in the Medical Device Industry for more than 30 years. His experience includes positions such as GM and VP, as well as high impact sales and marketing leadership roles at Major 500 Corporations (Medtronic/Covidien, BD/Bard, Cooper and Ciba). His achievements also involve work at start-up organizations (including working pre IPO on a successful IPO company).
 
As a Managing Director at MedWorld Advisors, Dave is focused on EXIT Strategies for the MedDevice, BioTech, DentalTech, DigitalHealthTec and OEM Medtech companies. For M&A, the goal is to help small and medium companies maximize their VALUE with their EXIT Strategy and/or achieve SUCCESS with their acquisition Strategy.

Dave and his Global team at MedWorld have led successful Exits across various Healthcare / MedTech / DigitalHealthTech / DentalTech market segments. Having completed international / cross-border deals, an important component to MedWorld’s success is their global reach and ability to cross boundaries to successfully facilitate transactions.

In addition to M&A achievements at MedWorld Advisors, his MedTech career worldwide results included completing distribution and licensing deals with international businesses, comprising of Major Fortune 500 companies (i.e., GE, Philips, Stryker, NK, Mindray, etc.) as well as smaller entities. These experiences have led to a global network of contacts with channel partners, large and small. Dave has been involved in “go-to market” strategies on every major developed continent (Europe, Asia, Africa, Australia, North and South America). 
 
For EXIT Strategy with Early-Stage Companies, Dave works with clients to prepare a foundation to maximize opportunities through identifying (and executing upon) key factors that create stakeholder value (I.e. Go-To-Market Strategies, Strategic Partnerships, International Channel Development, Roadmap Development, IP, Regulatory and Reimbursement Pathways, and Scalability). He collaborates with C-Suite Leaders as he leads the strategic development of client organizations and creates tactical execution plans that help exceed stakeholder and organizational objectives for short- and long term growth.

Dave is dedicated to the success of the MedTech, DentalTech, DigitalHealthTech, BioTech, Life Science and Healthcare Industries

Kenneth has established himself in the Commercial functions of the healthcare business, having cycled through Sales, Marketing and P&L roles. In recent years, he has built his success around driving difficult strategic shifts through organizations; in areas of business strategy and organizational transformation.

The hallmarks of his career are Strategy Execution, Growth Acceleration and Business-Model Innovation. This is due to his strategic agility, the bandwidth to go quickly from vision and strategy to operational details. Such strategic agility was built as he alternated between strategy and P&L roles.

He has a track record of transforming and turning around businesses as he deals well with ambiguity and build effective teams quickly. He has a preference for quick data-driven decisions, and these decisions are validated through hypothesis-testing and pilot implementation. Tracking Strategy Execution through data-driven metrics is also a distinct advantage he has over his peers.

He has managed businesses in the different phases of start-up, turn-around, sustaining success and realignment. Having extensive experience executing strategy in Asia, Europe and Latin America, he believes that what defines a true commercial leader is his ability to execute on strategy, not just formulate it.

In the area of Organizational and Leadership Development, he is passionate about “Fair-Process Leadership” and driving Diversity, Equity and Inclusion. He strongly believes that Purpose, Culture and Sustainability are key Strategy pillars for organizations to thrive in this new post-pandemic world and attract a new generation of exponential leaders.

He contributes his own time to mentoring aspiring Asian leaders in healthcare to impact their community and to advocacy work in healthcare capacity building in emerging economies, focusing on Cancer and Palliative care.